• Explore /
  • Poster
  • / Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

Abstract Video & Slides Poster

Authors

Meletios Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens, Athens, Greece

Meletios A. Dimopoulos , Peter M. Voorhees , Hartmut Goldschmidt , Ross I. Baker , Yingqi Shi , Els Rousseau , Robyn Monet Dennis , Robin L. Carson , S. Vincent Rajkumar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Plasma Cell Disorders

Clinical Trial Registration Number

NCT03301220

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS8075)

DOI

10.1200/JCO.2022.40.16_suppl.TPS8075

Abstract #

TPS8075

Poster Bd #

494b

Abstract Disclosures

Similar Posters

First Author: S.Vincent Rajkumar

First Author: Smith Giri

First Author: Hareth Nahi

First Author: Sebastian Grosicki